Symposium:
107. Bones and Bolts—Osteomyelitis and Orthopedic Device Infectious Diseases
Friday, October 9, 2015: 8:30 AM-10:00 AM
Room: 6--CF

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • identify the different modalities available for the diagnosis of osteomyelitis and orthopedic device infections
  • review their utility in different clinical settings
  • recognize the roles of the clinical pathology and clinical microbiology laboratories in this setting

Target Audience: Pharmacists, Nurses, Microbiologists, Members-in-training, Lab personnel, Investigators, Infectious diseases physicians, Healthcare workers, Fellows, Epidemiologists, Clinicians, Academicians

Tracks: Trainee, Epidemiology and Infection Control, Adult ID

Moderator:  Francisco M. Marty, MD, FIDSA, Brigham and Women's Hospital

Presentations:
8:30 AM
663
Diagnosis and Role of the Clinical Microbiology Laboratory
Robin Patel, MD, FIDSA, FRCP(C), D(ABMM), FACP, F(AAM)

9:00 AM
664
Treating to the Core
Parham Sendi, MD, Lecturer

9:30 AM
665
Diabetic Food Osteomyelitis: Diagnosis and Treatment
Benjamin Lipsky, MD, FACP, FIDSA

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: No CPE credit is offered for this session

ACPE Number:

Disclosures:

F. M. Marty, Astellas: Consultant and Grant Investigator , Consulting fee and Research grant
Chimerix: Consultant and Grant Investigator , Consulting fee and Research grant
Gilead: Grant Investigator , Consulting fee and Research grant
GlaxoSmithKline: Consultant and Grant Investigator , Consulting fee and Research grant
Merck: Consultant and Grant Investigator , Consulting fee and Research grant
Shire: Consultant and Grant Investigator , Consulting fee and Research grant
WHISCON: Consultant and Grant Investigator , Consulting fee and Research grant
Vertex: Consultant , Consulting fee
Alexion: Data Safety Monitoring Board member , Consulting fee

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.